ES2152664T3 - Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer. - Google Patents

Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer.

Info

Publication number
ES2152664T3
ES2152664T3 ES97919269T ES97919269T ES2152664T3 ES 2152664 T3 ES2152664 T3 ES 2152664T3 ES 97919269 T ES97919269 T ES 97919269T ES 97919269 T ES97919269 T ES 97919269T ES 2152664 T3 ES2152664 T3 ES 2152664T3
Authority
ES
Spain
Prior art keywords
prolin
hydroxy
cis
methyl
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97919269T
Other languages
English (en)
Inventor
Wilhelm Dr Hoerrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2152664T3 publication Critical patent/ES2152664T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMBINACION FORMADA POR CIS - 4 - HIDROXI L - PROLINA Y N - METIL - CIS - 4 - HIDROXI - L - PROLINA PARA UTILIZARSE COMO PRINCIPIO ACTIVO TERAPEUTICO EN PARTICULAR PARA EL TRATAMIENTO CONTRA EL CANCER. TAMBIEN SE DESCRIBE LA UTILIZACION DE LAS SUSTANCIAS INDIVIDUALES PARA TRATAR EL CANCER DE PROSTATA QUE ES SENSIBLE A LAS HORMONAS.
ES97919269T 1996-03-11 1997-03-11 Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer. Expired - Lifetime ES2152664T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19609454 1996-03-11

Publications (1)

Publication Number Publication Date
ES2152664T3 true ES2152664T3 (es) 2001-02-01

Family

ID=7787909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97919269T Expired - Lifetime ES2152664T3 (es) 1996-03-11 1997-03-11 Combinacion de cis-4-hidroxi-l-prolina y n-metil-cis-4-hidroxi-l-prolina para aplicacion como agente terapeutico, especialmente para el tratamiento contra el cancer.

Country Status (8)

Country Link
US (1) US6066665A (es)
EP (1) EP0912172B1 (es)
JP (1) JP2000506174A (es)
AU (1) AU2380097A (es)
CA (1) CA2248765A1 (es)
DE (2) DE19780207D2 (es)
ES (1) ES2152664T3 (es)
WO (1) WO1997033578A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264505T1 (de) * 1999-05-04 2004-04-15 Hoerrmann Wilhelm Labormässige untersuchung einer körperflüssigkeits- oder gewebeprobe
DE10359829A1 (de) * 2003-12-12 2005-07-21 Salama, Zoser B., Dr.Rer.Nat. Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
CA2548391A1 (en) * 2003-12-18 2005-06-30 Zoser B. Salama Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1281288C (en) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Tumor therapy
US5665371A (en) * 1985-05-20 1997-09-09 Hoerrmann; Wilhelm Medicines which contain derivatives of proline or hydroxyproline
DE3518078A1 (de) * 1985-05-20 1986-11-20 Wilhelm Dr. 8127 Iffeldorf Hoerrmann Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten

Also Published As

Publication number Publication date
DE59702322D1 (de) 2000-10-12
WO1997033578A1 (de) 1997-09-18
JP2000506174A (ja) 2000-05-23
EP0912172B1 (de) 2000-09-06
CA2248765A1 (en) 1997-09-18
EP0912172A1 (de) 1999-05-06
DE19780207D2 (de) 1999-03-11
AU2380097A (en) 1997-10-01
US6066665A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
BRPI0514116A (pt) artigos absorventes compreendendo um agente modificador de exsudado corpóreo e uma formulação para cuidado da pele
ES2185050T3 (es) Utilizacion de la octoxiglicerina en una composicion cosmetica y/o dermatologica como agente activo para el tratamiento de la seborrea y/o del acne.
AR042815A1 (es) Dispositivo de suministro de agente activo que tiene miembros compuestos
AR021371A1 (es) Aposito
ES2139002T3 (es) Terapia medicamentosa citotoxica.
NO20020299D0 (no) Behandling og sammensetning for oppnåelse av antialdring av hud med Corneum Protease aktivering
AR022404A1 (es) Metodo y agentes para la terapia de radiacion mejorada
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
AR013024A1 (es) Articulo absorbente descartable que tiene una composicion para el cuidado de la piel que contiene a un inhibidor de enzima y metodo para reducir laactividad enzimatica.
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
NO20034684D0 (no) Innretning for administrering av midler gjennom stratum corcum
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
BR0214481A (pt) Método e composição para potenciação de um analgésico opiáceo
PT971694E (pt) Preparacoes de medicamentos para o tratamento de disfuncao sexual
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ES2143467T3 (es) Agente terapeutico para el tratamiento de las heridas.
ES2192840T3 (es) Laxante osmotico no fermentado para tratar y prevenir cancer colorrectal.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 912172

Country of ref document: ES